Xiang Xu

Xiang Xu, PhD, DABT, is a seasoned scientist with extensive experience in drug discovery and development across various therapeutic areas, including neurodegenerative diseases, cancer, fibrosis, and immunological disorders. Currently serving as the Head of In Vivo Pharmacology at Nitrase Therapeutics since August 2022, Xiang Xu previously worked at Blade Therapeutics, focusing on anti-fibrosis and anti-neurodegenerative drug initiatives. Additional experience includes a scientific role at Hangzhou Xiangsheng Pharmaceuticals, where Xiang Xu developed products targeting inflammation and irritation, and a research position at the University of California, San Francisco, emphasizing infectious and inflammatory diseases. Educational credentials encompass a PhD in Pharmacology from The Hebrew University of Jerusalem, a postdoctoral fellowship in infectious diseases from the University of California, San Francisco, and advanced degrees in Pathology and Pediatrics.